tiprankstipranks
Trending News
More News >
Jacobson Pharma Corporation Limited (HK:2633)
:2633
Hong Kong Market
Advertisement

Jacobson Pharma Corporation Limited (2633) AI Stock Analysis

Compare
3 Followers

Top Page

HK:2633

Jacobson Pharma Corporation Limited

(2633)

Rating:74Outperform
Price Target:
HK$2.00
â–²(18.34%Upside)
Jacobson Pharma Corporation Limited demonstrates strong financial performance and positive technical indicators, which support a high overall score. The stock's valuation is reasonable with a solid dividend yield, appealing to income-focused investors. Despite strong momentum, caution is advised due to potential overbought signals.

Jacobson Pharma Corporation Limited (2633) vs. iShares MSCI Hong Kong ETF (EWH)

Jacobson Pharma Corporation Limited Business Overview & Revenue Model

Company DescriptionJacobson Pharma Corporation Limited (2633) is a leading pharmaceutical company based in Hong Kong. It operates in the research, development, production, marketing, and sales of generic drugs, proprietary medicines, and health supplements. The company offers a comprehensive portfolio of products, catering to various therapeutic areas including cardiovascular, respiratory, anti-infective, and gastrointestinal, among others. Jacobson Pharma is recognized for its strong market presence in Hong Kong and its expanding footprint in other Asian regions.
How the Company Makes MoneyJacobson Pharma Corporation Limited primarily generates revenue through the sale of its generic drugs and proprietary medicines. The company benefits from a broad portfolio of over-the-counter and prescription medications, which are distributed through a well-established network of healthcare institutions, pharmacies, and retail outlets. Additionally, the company engages in strategic partnerships and alliances to enhance its product offerings and expand market reach. Jacobson Pharma also places significant emphasis on research and development to innovate and introduce new products, thus ensuring sustained revenue growth. Furthermore, the company's expansion into health supplements and its efforts to penetrate international markets contribute to its diversified revenue streams.

Jacobson Pharma Corporation Limited Financial Statement Overview

Summary
Jacobson Pharma Corporation Limited exhibits solid financial performance with strong profitability, efficient operations, and effective cash management. While revenue growth showed a slight decline recently, the company's overall financial health remains commendable.
Income Statement
78
Positive
Jacobson Pharma Corporation Limited has demonstrated a strong performance in its income statement. The gross profit margin is healthy, indicating effective cost management. The net profit margin reflects profitability, with consistent growth in net income over the years. Revenue growth has been positive, though there was a slight decline in the most recent year. EBIT and EBITDA margins are solid, showing operational efficiency. Overall, the company maintains a robust financial health in its income statement metrics.
Balance Sheet
70
Positive
The balance sheet of Jacobson Pharma indicates a stable financial position with a solid equity base. The debt-to-equity ratio suggests a moderate level of leverage, manageable within industry norms. Return on Equity (ROE) is favorable, showing effective use of equity capital to generate profits. The equity ratio is strong, signifying a substantial proportion of assets financed by shareholders' equity. However, the company should monitor its debt levels to ensure long-term financial flexibility.
Cash Flow
75
Positive
Cash flow analysis reveals a strong operating cash flow, indicating excellent cash generation capability. The free cash flow has grown consistently, supporting reinvestment opportunities and shareholder returns. Ratios of operating and free cash flow to net income demonstrate effective cash management. The company has improved its free cash flow generation, although capital expenditures have seen fluctuations. Overall, the cash flow statement highlights robust cash flow management.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue1.58B1.47B1.79B1.60B1.45B
Gross Profit692.94M620.48M747.17M620.52M534.15M
EBITDA558.87M489.81M462.04M415.49M377.20M
Net Income300.83M266.97M251.04M177.67M173.71M
Balance Sheet
Total Assets3.65B3.49B5.38B4.76B4.87B
Cash, Cash Equivalents and Short-Term Investments509.05M411.94M1.04B478.65M480.35M
Total Debt773.21M749.38M1.60B1.41B1.65B
Total Liabilities1.17B1.09B2.12B1.80B2.01B
Stockholders Equity2.45B2.37B2.74B2.49B2.39B
Cash Flow
Free Cash Flow278.39M354.85M585.23M345.89M347.99M
Operating Cash Flow526.78M484.36M648.24M409.76M411.35M
Investing Cash Flow-297.76M43.34M-44.09M-52.75M-375.40M
Financing Cash Flow-131.30M-1.05B-45.64M-357.89M21.36M

Jacobson Pharma Corporation Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.69
Price Trends
50DMA
1.55
Positive
100DMA
1.38
Positive
200DMA
1.15
Positive
Market Momentum
MACD
0.02
Positive
RSI
49.94
Neutral
STOCH
74.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2633, the sentiment is Neutral. The current price of 1.69 is above the 20-day moving average (MA) of 1.68, above the 50-day MA of 1.55, and above the 200-day MA of 1.15, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 49.94 is Neutral, neither overbought nor oversold. The STOCH value of 74.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2633.

Jacobson Pharma Corporation Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
HK$3.48B10.0821.15%10.62%20.89%24.98%
79
Outperform
HK$2.50B12.6219.22%3.23%18.06%80.57%
74
Outperform
HK$3.17B11.0212.47%3.89%7.43%21.88%
74
Outperform
HK$6.32B6.9411.61%6.03%-18.09%-15.08%
73
Outperform
HK$2.01B3.2918.33%5.57%-9.95%67.56%
67
Neutral
HK$1.02B10.945.04%2.60%32.95%456.69%
51
Neutral
$7.35B0.50-65.61%2.47%15.28%1.44%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2633
Jacobson Pharma Corporation Limited
1.64
1.10
203.70%
HK:6896
Golden Throat Holdings Group Co Ltd
4.71
1.91
68.21%
HK:2877
China Shineway Pharmaceutical Group Limited
8.14
0.52
6.82%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.34
0.32
31.37%
HK:2161
JBM (Healthcare) Ltd.
2.96
2.05
225.27%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.73
0.69
66.35%

Jacobson Pharma Corporation Limited Corporate Events

Jacobson Pharma Announces AGM Results and Strategic Appointments
Jul 28, 2025

Jacobson Pharma Corporation Limited announced the results of its Annual General Meeting held on July 28, 2025, where all proposed resolutions were passed. Key outcomes include the approval of final and special dividends, re-election of directors, and the appointment of a new independent non-executive director. These decisions reflect the company’s strategic direction and commitment to shareholder value, potentially impacting its market position and stakeholder confidence.

Jacobson Pharma Announces Board Composition and Governance Structure
Jul 28, 2025

Jacobson Pharma Corporation Limited announced the composition and roles of its board of directors and board committees, highlighting the leadership of Mr. Sum Kwong Yip, Derek as Chairman, CEO, and Executive Director. The announcement underscores the company’s governance structure, which includes committees focused on audit, remuneration, nomination, executive, and environmental, social, and governance matters, reflecting its commitment to comprehensive corporate governance.

Jacobson Pharma Updates Nomination Committee Terms to Boost Diversity and Governance
Jul 28, 2025

Jacobson Pharma Corporation Limited has revised the terms of reference for its Nomination Committee, which plays a crucial role in identifying and evaluating candidates for the board of directors, as well as overseeing policies related to board and workforce diversity. The updated terms emphasize the importance of independent non-executive directors and gender diversity within the committee. This move is expected to enhance the governance and diversity of the company’s leadership, potentially improving its strategic decision-making and aligning with broader industry trends towards inclusivity.

Jacobson Pharma Announces Key Dates for AGM and Dividends
Jul 11, 2025

Jacobson Pharma Corporation Limited has announced key dates for its upcoming Annual General Meeting and proposed dividends. The company has set the record date for shareholders to attend and vote at the meeting on July 28, 2025, with the register of members closed from July 22 to July 28, 2025. Additionally, the record date for entitlement to the proposed final and special dividends is set for August 14, 2025, with the register closed from August 13 to August 14, 2025. These announcements are crucial for shareholders as they outline the timeline for participation in corporate governance and potential financial benefits.

Jacobson Pharma Announces Virtual AGM and Dividend Plans
Jul 3, 2025

Jacobson Pharma Corporation Limited has announced its upcoming annual general meeting to be held virtually on July 28, 2025. Key agenda items include the approval of financial statements, declaration of final and special dividends, re-election of directors, and the reappointment of KPMG as auditor. Additionally, the company seeks shareholder approval for a mandate to repurchase up to 10% of its issued shares, which could impact the company’s stock liquidity and shareholder value.

Jacobson Pharma Reports Strong Financial Growth in 2025
Jun 13, 2025

Jacobson Pharma Corporation Limited announced its annual financial results for the year ending March 31, 2025, reporting a revenue increase of 7.4% to approximately HK$1,576.9 million. The company’s profit from operations rose by 24.5% to HK$414.6 million, and profit from continuing operations increased by 43.1% to HK$300.8 million. The Board has recommended a final cash dividend of HK5.50 cents per share and a special cash dividend of HK6.00 cents per share, reflecting a strong financial performance and commitment to returning value to shareholders.

Jacobson Pharma Announces Final Dividend for FY2025
Jun 13, 2025

Jacobson Pharma Corporation Limited has announced a final ordinary cash dividend of HKD 0.055 per share for the financial year ending March 31, 2025. This announcement reflects the company’s commitment to returning value to its shareholders and may enhance its attractiveness to investors, potentially impacting its market positioning positively.

Jacobson Pharma Announces Special Dividend for FY 2025
Jun 13, 2025

Jacobson Pharma Corporation Limited has announced a special dividend of HKD 0.06 per share for the financial year ending 31 March 2025. This move reflects the company’s strong financial performance and commitment to delivering shareholder value. The dividend will be paid on 28 August 2025, with the ex-dividend date set for 11 August 2025, and the record date on 14 August 2025. This announcement is likely to positively impact the company’s market positioning and investor confidence.

Jacobson Pharma Announces Director Retirement
Jun 13, 2025

Jacobson Pharma Corporation Limited announced the retirement of Professor Lam Sing Kwong, Simon from his role as an independent non-executive director, effective after the annual general meeting on July 28, 2025. Professor Lam, who has served since April 2016, will also step down from his positions on various committees, and the company is in the process of identifying a suitable replacement.

Jacobson Pharma Schedules Board Meeting to Review Annual Results
May 30, 2025

Jacobson Pharma Corporation Limited has announced a board meeting scheduled for June 13, 2025, to discuss and approve the company’s annual results for the fiscal year ending March 31, 2025. The meeting will also consider the recommendation of a final dividend and address any other business matters, potentially impacting the company’s financial strategy and stakeholder interests.

Jacobson Pharma Projects Over 40% Profit Increase for FY2025
May 26, 2025

Jacobson Pharma Corporation Limited has announced a positive profit alert, expecting a more than 40% increase in profit from continuing operations for the fiscal year ending March 2025 compared to the previous year. This growth is attributed to strong performance in specialty medicines and generic drugs, new product launches, and effective cost control measures. Additionally, the profit attributable to equity shareholders is anticipated to rise by over 10%, following the distribution of JBM Healthcare shares as a special dividend.

Jacobson Pharma Expands Stake in Tycoon Group Amid Market Volatility
May 16, 2025

Jacobson Pharma Corporation Limited announced its decision to increase its investment in Tycoon Group Holdings Limited by subscribing to additional shares. Despite a recent decline in Tycoon Group’s share prices, Jacobson Pharma views this as a strategic opportunity to enhance its long-term investment portfolio, given Tycoon Group’s resilient operational performance and favorable asset valuation. This move is expected to strengthen Jacobson Pharma’s position in the market and potentially offer significant returns to its stakeholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025